Drug development for recurrent and refractory classical Hodgkin lymphoma.

Abstract:

:Classical Hodgkin lymphoma (cHL) is highly treatable with chemotherapy alone or combined modality therapy. High dose therapy and autologous stem cell transplant is considered standard of care for patients who relapse. For patients who relapse following transplant or who are not candidates for high dose therapy, prognosis is poor, and new treatment strategies are needed. Targeted therapies for relapsed Hodgkin lymphoma include monoclonal antibodies directed at cell surface antigens, immunoconjugates, bispecific constructs created to recruit host effector cells and radioimmunotherapy. In Epstein-Barr virus (EBV)-associated Hodgkin lymphoma, cytotoxic T lymphocytes directed at EBV antigens have been utilised in clinical trials with some success. Additionally, the immunomodulatory agents thalidomide and lenalidomide, and new classes of drugs such as the mammalian target of rapamycin inhibitors and histone deacetylase inhibitors hold promise in relapsed Hodgkin lymphoma.

journal_name

Leuk Lymphoma

journal_title

Leukemia & lymphoma

authors

Wildes TM,Bartlett NL

doi

10.1080/10428190902756586

subject

Has Abstract

pub_date

2009-04-01 00:00:00

pages

529-40

issue

4

eissn

1042-8194

issn

1029-2403

pii

910512842

journal_volume

50

pub_type

杂志文章,评审
  • Non-Hodgkin lymphoma expressing high levels of the danger-signalling protein HMGB1.

    abstract::HMGB1 is a high mobility group protein that can act either as a DNA binding protein or extracellularly as a cytokine-like danger signal. Extracellular HMGB1, either actively secreted or passively released by necrotic cells, is linked to inflammation and cancer. Herein, the results of a study to quantify the expression...

    journal_title:Leukemia & lymphoma

    pub_type: 杂志文章

    doi:10.1080/10428190802064909

    authors: Meyer A,Staratschek-Jox A,Springwald A,Wenk H,Wolf J,Wickenhauser C,Bullerdiek J

    更新日期:2008-06-01 00:00:00

  • Treatment of Philadelphia Chromosome Positive (Ph +) Chronic Myelogenous Leukemia in Blast Crisis and Ph + Acute Leukemia with High Dose Cytosine Arabinoside (HDARAC).

    abstract::High dose cytosine arabinoside (HDARAC) was administered to eleven patients in the blastic phase of Philadelphia (Ph) chromosome positive chronic myelogenous leukemia (CML). Four patients presented in blastic phase and in seven patients blastic transformation had evolved from a previous chronic phase. All patients had...

    journal_title:Leukemia & lymphoma

    pub_type: 杂志文章

    doi:10.3109/10428199109068053

    authors: Kempin S,Arlin Z,Berman E,Gee T,Mertelsmann R,Andreeff M,Kolitz J,Jhanwar S,Myers J,Clarkson B

    更新日期:1991-01-01 00:00:00

  • Health-related quality of life in survivors of lymphoma: a systematic review and methodological critique.

    abstract::Survival rates for Hodgkin lymphoma and non-Hodgkin lymphoma have improved in recent years. However, these improvements are associated with various late effects, which can compromise health-related quality of life (HRQoL). Improving HRQoL is a significant goal in oncology, and increasingly one of the primary outcomes ...

    journal_title:Leukemia & lymphoma

    pub_type: 杂志文章,评审

    doi:10.3109/10428191003587263

    authors: Arden-Close E,Pacey A,Eiser C

    更新日期:2010-04-01 00:00:00

  • Mutations within the 5' region of FAS/CD95 gene in nodal diffuse large B-cell lymphoma.

    abstract::CD95 is a cell-surface receptor that mediates apoptosis. A possible association between CD95 mutations and extranodal diffuse large B-cell lymphomas (DLBCL) has been reported. To further elucidate this question, a mutation analysis within the 5' region and exon 9 of CD95 was performed in a series of 66 DLBCL patients,...

    journal_title:Leukemia & lymphoma

    pub_type: 杂志文章

    doi:10.1080/10428190701230858

    authors: Scholl V,Stefanoff CG,Hassan R,Spector N,Renault IZ

    更新日期:2007-05-01 00:00:00

  • Fine-Needle Aspiration Cytology and Immunocytochemistry of Abdominal Non-Hodgkin's Lymphomas.

    abstract::The cytomorphology and immunologic characteristics of cells obtained by fine-needle aspiration biopsy of 34 consecutive patients with abdominal lymphomas were analyzed. Nineteen patients had no previous diagnosis, while 15 had previously known or suspected lymphomas. On cytology 21 high-grade and 13 low-intermediate-g...

    journal_title:Leukemia & lymphoma

    pub_type: 杂志文章

    doi:10.3109/10428198909042461

    authors: Liliemark J,Tani E,Christensson B,Svedmyr E,Skoog L

    更新日期:1989-01-01 00:00:00

  • Abundant expression of interleukin-21 receptor in follicular lymphoma cells is associated with more aggressive disease.

    abstract::Recombinant interleukin-21 (IL-21) has potential utility in cancer therapy. Stimulation with IL-21 can induce apoptosis in follicular lymphoma (FL) cells, and existing studies have suggested that IL-21 signaling may function in tumor suppression. In order to elucidate the relationship between IL-21 receptor (IL-21R) e...

    journal_title:Leukemia & lymphoma

    pub_type: 杂志文章

    doi:10.3109/10428194.2012.742522

    authors: Wood B,Sikdar S,Choi SJ,Virk S,Alhejaily A,Baetz T,LeBrun DP

    更新日期:2013-06-01 00:00:00

  • Chromosomal imbalances in pediatric Burkitt-like lymphoma and review of the literature in relation to other germinal center derived B-cell tumors.

    abstract::This study reports on the cytogenetic features of a novel case of pediatric Burkitt-like lymphoma (BLL), that adds to the three published. Four groups of cytogenetic abnormalities were detected in the present case: (1) imbalances shared by most germinal center (GC) derived B-cell tumors including BLL (+1q, -6q, -8p, +...

    journal_title:Leukemia & lymphoma

    pub_type: 杂志文章

    doi:10.1080/10428190600880118

    authors: Pezzolo A,Cinti R,Negri F,Parodi F,Garaventa A,Gambini C,Pistoia V

    更新日期:2006-11-01 00:00:00

  • Clinical dissection of multicentric Castleman disease.

    abstract::This study investigated the prognostic factors of Castleman disease (CD) and focused specifically on multicentric CD (MCD). Seventy patients with CD were studied. Forty-three patients (61.5%) had unicentric CD (UCD) and 27 patients (38.5%) had MCD. Thirty-six patients with UCD (83.7%) underwent surgical excision, and ...

    journal_title:Leukemia & lymphoma

    pub_type: 杂志文章

    doi:10.3109/10428194.2011.574759

    authors: Shin DY,Jeon YK,Hong YS,Kim TM,Lee SH,Kim DW,Kim I,Yoon SS,Heo DS,Park S,Kim BK

    更新日期:2011-08-01 00:00:00

  • Molecular variant of hairy cell leukemia with poor prognosis.

    abstract::Hairy cell leukemia variant (HCLv), described 30 years ago, was reported to present with high disease burden and less often leukopenia, and later was reported to be resistant to purine analogs. Patients with HCLv were overrepresented among patients with HCL seeking relapsed/refractory trials. To compare clinical and m...

    journal_title:Leukemia & lymphoma

    pub_type: 杂志文章

    doi:10.3109/10428194.2011.565841

    authors: Arons E,Kreitman RJ

    更新日期:2011-06-01 00:00:00

  • Feasibility of thiotepa addition to the fludarabine-busulfan conditioning with tacrolimus/sirolimus as graft vs host disease prophylaxis.

    abstract::In classical reduced-intensity conditioning (RIC) regimens, including the fludarabine and busulphan (BF) combination, sirolimus and tacrolimus (SIR-TAC) as graft vs host disease (GVHD) prophylaxis has shown acceptable results. The outcomes of SIR-TAC in a more intense RIC regimen as Thiotepa-fludarabine-busulfan (TBF)...

    journal_title:Leukemia & lymphoma

    pub_type: 杂志文章

    doi:10.1080/10428194.2020.1788015

    authors: Fox ML,García-Cadenas I,Pérez AM,Villacampa G,Piñana JL,Ortí G,Montoro J,Roldán E,Bosch Vilaseca A,Martino R,Salamero O,Saavedra S,Hernandez-Boluda JC,Esquirol A,Sierra J,Sanz J,Solano C,Bosch F,Barba P,Valcarcel D

    更新日期:2020-08-01 00:00:00

  • Daratumumab for the treatment of AL amyloidosis.

    abstract::Autologous stem cell transplantation (ASCT) has been used as treatment for immunoglobulin light-chain (AL) amyloidosis for over two decades with improving outcomes; however, the majority of patients are not candidates for this therapy at diagnosis. Novel agents such as immunomodulatory drugs, proteasome inhibitors, an...

    journal_title:Leukemia & lymphoma

    pub_type: 杂志文章,评审

    doi:10.1080/10428194.2018.1485914

    authors: Sidiqi MH,Gertz MA

    更新日期:2019-02-01 00:00:00

  • Mutation of the ATM gene is not involved in the pathogenesis of either follicle center lymphoma or its transformation to higher-grade lymphoma.

    abstract::Loss of function of the ataxia-telangiectasia mutated (ATM) gene, located on human chromosome 11q22-23, is the cause of ataxia-telangiectasia (A-T), which is associated with an extremely high risk for lymphoma. Abnormalities in 11q22-23, including deletions and mutations of the ATM gene, have been reported in T-cell p...

    journal_title:Leukemia & lymphoma

    pub_type: 杂志文章

    doi:10.1080/10428190290021623

    authors: Lossos IS,Thorstenson YR,Wayne TL,Oefner PJ,Levy R,Chu G

    更新日期:2002-05-01 00:00:00

  • Clinical features, treatment and outcome in a series of 93 patients with low-grade gastric MALT lymphoma.

    abstract::The purpose of this paper is to report the clinical characteristics and treatment outcome following different therapeutic approaches in a large series of patients with primary low-grade MALT lymphoma of the stomach. A total of ninety-three patients (median age 63 years) were reviewed. The patients were treated by diff...

    journal_title:Leukemia & lymphoma

    pub_type: 临床试验,杂志文章

    doi:10.3109/10428199709050889

    authors: Pinotti G,Zucca E,Roggero E,Pascarella A,Bertoni F,Savio A,Savio E,Capella C,Pedrinis E,Saletti P,Morandi E,Santandrea G,Cavalli F

    更新日期:1997-08-01 00:00:00

  • Clinical characteristics of non-Hodgkin's lymphoma as a second primary tumor: a population-based survey.

    abstract::Data from 29,845 patients with lymphomas, 981 of whom had lymphoma as a second primary tumor, registered in the Surveillance Epidemiology and End Results (SEER) program in the U.S.A. between 1973 and 1986 were analyzed. The characteristics of the 274 patients with lymphoma as a second tumor who had received chemothera...

    journal_title:Leukemia & lymphoma

    pub_type: 杂志文章

    doi:10.3109/10428199609051621

    authors: Robinson E,Bar-Deroma R,Epelbaum R,Rennert G,Neugut AI

    更新日期:1996-01-01 00:00:00

  • Clinical characteristics and prognostic significance of chronic myeloid leukemia with rare BCR-ABL1 transcripts.

    abstract::The prognostic significance of rare BCR-ABL1 transcripts is uncertain in the tyrosine kinase inhibitor (TKI) era. In this retrospective study, 40 (1.7%) patients with rare BCR-ABL1 transcripts were identified from a cohort of 2331 chronic myeloid leukemia (CML) patients; 4 types of rare transcripts were identified, in...

    journal_title:Leukemia & lymphoma

    pub_type: 杂志文章

    doi:10.1080/10428194.2019.1607329

    authors: Xue M,Wang Q,Huo L,Wen L,Yang X,Wu Q,Pan J,Cen J,Ruan C,Wu D,Chen S

    更新日期:2019-12-01 00:00:00

  • Report of novel chromosomal abnormalities in a series of 130 chronic lymphocytic leukemia patients studied by classic cytogenetic analysis.

    abstract::One-hundred-and-thirty typical, unselected CLL cases were studied by conventional cytogenetic analysis. Seventy-three patients (56.2%) had normal karyotype ('normal sub-group'), while 57/130 patients (43.8%) had abnormal karyotype. Twenty-two of 57 patients (38.6%) carried more than one abnormality. Six novel chromoso...

    journal_title:Leukemia & lymphoma

    pub_type: 杂志文章

    doi:10.1080/10428190600881447

    authors: Athanasiadou A,Stamatopoulos K,Tsezou A,Vadikolia C,Asteriou O,Fassas A,Anagnostopoulos A

    更新日期:2006-10-01 00:00:00

  • Acquired C1 esterase inhibitor deficiency in lymphomas: prevalence, symptoms, and response to treatment.

    abstract::We retrospectively studied the prevalence of C1 esterase inhibitor (C1 INH) deficiency in 131 patients with various lymphomas. We determined C1 INH activity, C1 INH antigen, and C4 concentration at diagnosis and after chemotherapy. In follicular lymphoma (FL), diffuse large B-cell lymphoma (DLBCL) and chronic lymphocy...

    journal_title:Leukemia & lymphoma

    pub_type: 杂志文章

    doi:10.3109/10428194.2015.1131273

    authors: Bekos C,Perkmann T,Krauth M,Raderer M,Lechner K,Jaeger U

    更新日期:2016-09-01 00:00:00

  • Pro-survival role of protein kinase C epsilon in Philadelphia chromosome positive acute leukemia.

    abstract::Durable responses to imatinib monotherapy are rarely seen in aggressive forms of Philadelphia chromosome positive (Ph+) leukemias. To investigate the possible cause of treatment failure we examined the role of protein kinase C epsilon (PKCE), an oncogene highly implicated in the development of solid tumors and resista...

    journal_title:Leukemia & lymphoma

    pub_type: 杂志文章

    doi:10.3109/10428194.2015.1043545

    authors: Loi TH,Dai P,Carlin S,Melo JV,Ma DDF

    更新日期:2016-02-01 00:00:00

  • Vincristine degradation by serum from leukemic patients: role of myeloperoxidase.

    abstract::Myeloperoxidase (MPO) has been shown to catalyze the in vitro degradation of vincristine (VCR). Given that MPO is a lysosomal enzyme that can be released into the circulation by both normal activated and leukemic myeloid cells, we investigated the possibility that sera from patients with acute myeloblastic leukemia (A...

    journal_title:Leukemia & lymphoma

    pub_type: 杂志文章

    doi:10.3109/10428199609052426

    authors: Schlaifer D,Duchayne E,Demur C,Alvinerie P,Muller C,Attal M,Cooper MR,Payen C,Monsarrat B,Myers CE,Pris J,Laurent G

    更新日期:1996-02-01 00:00:00

  • Outcome of graft failure after allogeneic stem cell transplant: study of 89 patients.

    abstract::Strategies for reversing graft failure (GF) after allogeneic stem cell transplant (SCT) depend on the options available in each situation. GF was reported in 16 Spanish institutions from January 2006 to July 2011. Primary GF was defined as an absolute neutrophil count (ANC) > 0.5 × 10(9)/L not reached by day + 28 afte...

    journal_title:Leukemia & lymphoma

    pub_type: 杂志文章,多中心研究

    doi:10.3109/10428194.2014.930849

    authors: Ferrà C,Sanz J,Díaz-Pérez MA,Morgades M,Gayoso J,Cabrera JR,Villaescusa T,Sampol MA,Fernández-Avilés F,Solano C,Ortín M,Duarte R,Cuesta M,Heras I,de la Serna J,Moraleda JM,Barrenetxea C,González-Vicent M,Sanz G,Ribe

    更新日期:2015-03-01 00:00:00

  • Prognostic impact of low muscle mass and low muscle density in patients with diffuse large B-cell lymphoma.

    abstract::Low muscle mass (LMM) and low muscle density (LMD) are increasingly recognized as prognostic factors for survival in different malignancies. This study determined the association of LMM and LMD with survival in DLBCL (diffuse large B-cell lymphoma) patients. CT-based measurement of muscle was performed in 164 DLBCL pa...

    journal_title:Leukemia & lymphoma

    pub_type: 杂志文章

    doi:10.1080/10428194.2020.1737686

    authors: Rier HN,Kharagjitsing H,van Rosmalen J,van Vugt J,Westerweel PE,de Jongh E,Kock M,Levin MD

    更新日期:2020-07-01 00:00:00

  • Lymphomatous proptosis as a novel feature of mantle cell lymphoma.

    abstract::We describe eight cases of acute proptosis due to mantle cell lymphoma (MCL), among 26 consecutive MCL cases. The median time of onset was 29 months (range 0-102) from diagnosis. Two cases presented initially with orbital masses while five as sudden disease progression after multiple courses of chemotherapy. In each c...

    journal_title:Leukemia & lymphoma

    pub_type: 杂志文章

    doi:10.1080/10428190500301058

    authors: Hon C,Chan RT,Ma ES,Shek TW,Yau K,Au WY

    更新日期:2006-01-01 00:00:00

  • Comparison of clinical features and survival between young and old chronic lymphocytic leukemia patients: a single center study from Turkey.

    abstract::We aimed to investigate whether the clinical characteristics, the rate of treatment demand and survival differ between chronic lymphocytic leukemia (CLL) patients <65 years (y) and ≥65 y. Sixty three (46%) patients were <65 y and 74 (54%) were ≥65 y. 28.6% (18/63) of the patients <65 required treatment, while this rat...

    journal_title:Leukemia & lymphoma

    pub_type: 杂志文章

    doi:10.1080/10428194.2018.1509316

    authors: Eren R,Karişmaz A,Karataş D,Doğu MH,Altindal Ş,Yokuş O,Suyani E

    更新日期:2019-03-01 00:00:00

  • Mycobacterium-avium-intracellulare complex infection following 2-chlorodeoxyadenosine therapy for hairy cell leukaemia.

    abstract::2-Chlorodeoxyadenosine (2-CdA) is associated with prolonged suppression of CD4 lymphocytes. Cases of tuberculosis or mycobacterium avium intracellulare complex (MAC) infection complicating 2-CdA administration have not been reported despite the low CD4 counts. We report a patient with Hairy Cell Leukaemia (HCL) who de...

    journal_title:Leukemia & lymphoma

    pub_type: 杂志文章

    doi:10.3109/10428190009148413

    authors: Broady R,Roberts S,Hawkins T

    更新日期:2000-02-01 00:00:00

  • Prognostic implications of extranodal involvement in patients with diffuse large B-cell lymphoma treated with rituximab and cyclophosphamide, doxorubicin, vincristine, and prednisone.

    abstract::The addition of rituximab (R) to standard CHOP (cyclophosphamide, doxorubicin, vincristine, and prednisone) chemotherapy has altered the significance of previously recognized prognostic factors. We sought to re-examine the prognostic utility of (1) the number of extranodal sites of disease involvement, and (2) a prima...

    journal_title:Leukemia & lymphoma

    pub_type: 杂志文章

    doi:10.3109/10428194.2010.504872

    authors: Hui D,Proctor B,Donaldson J,Shenkier T,Hoskins P,Klasa R,Savage K,Chhanabhai M,Gascoyne RD,Connors JM,Sehn LH

    更新日期:2010-09-01 00:00:00

  • Treatment of refractory acute leukemia with timed sequential chemotherapy using topotecan followed by etoposide + mitoxantrone (T-EM) and correlation with topoisomerase II levels.

    abstract::A phase I/II clinical study evaluated 17 patients with refractory/recurrent acute leukemia treated with 1.5 mg/m2/day topotecan on days 1-3 followed by etoposide (100 mg/m2/day)+mitoxantrone (10 mg/m2/day) on days 4, 5 and 9, 10. Timed sequential chemotherapy using the topoisomerase I-inhibitor topotecan before the to...

    journal_title:Leukemia & lymphoma

    pub_type: 临床试验,杂志文章

    doi:10.1080/10428190290021339

    authors: Mainwaring MG,Rimsza LM,Chen SF,Gomez SP,Weeks FW,Reddy V,Lynch J,May WS,Kahn S,Moreb J,Leather H,Braylan R,Rowe TC,Fieniewicz KJ,Wingard JR

    更新日期:2002-05-01 00:00:00

  • Role of [18F]-fluoro-2-deoxy-D-glucose positron emission tomography in early and late therapy assessment of patients with advanced Hodgkin lymphoma treated with bleomycin, etoposide, adriamycin, cyclophosphamide, vincristine, procarbazine and prednisone.

    abstract::The prognostic value of positron emission tomography (PET) in early therapy response assessment, after completion of chemotherapy and 3 months after the end of treatment in advanced Hodgkin lymphoma (HL) remains to be defined. We report the results of 69 patients with first presentation of advanced HL. [18F]-fluoro-2-...

    journal_title:Leukemia & lymphoma

    pub_type: 杂志文章

    doi:10.3109/10428194.2011.603444

    authors: Markova J,Kahraman D,Kobe C,Skopalova M,Mocikova H,Klaskova K,Dedeckova K,Eich HT,Böll B,Dietlein M,Kozak T

    更新日期:2012-01-01 00:00:00

  • Myasthenia gravis and lymphoblastic lymphoma involving the thymus: a rare association.

    abstract::Myasthenia gravis (MG) is an autoimmune neuromuscular junction disease. An association between thymic epithelial neoplasms and MG is well known. However, it is rarely associated with hematologic malignancies. In particular, very few cases of lymphoblastic lymphoma involving the thymus and MG have been reported. Here w...

    journal_title:Leukemia & lymphoma

    pub_type: 杂志文章

    doi:10.3109/10428190109064612

    authors: Uner AH,Abali H,Engin H,Akyol A,Ruacan S,Tan E,Güllü I,Altundağ K,Güler N

    更新日期:2001-07-01 00:00:00

  • Predictive value of karyotype on outcome of autotransplants for acute myeloid leukemia in second remission.

    abstract::The impact of karyotype on the outcome of patients who undergo autotransplant for acute myeloid leukemia (AML) in second remission (CR2) has not been explored. We evaluated the outcomes of 40 patients who proceeded to autotransplant for AML in CR2 at 2 centers. The median age at autotransplant was 50 years (18-64 year...

    journal_title:Leukemia & lymphoma

    pub_type: 杂志文章,多中心研究

    doi:10.1080/10428190400025112

    authors: Song KW,Mollee PN,Hogge DE,Gupta V,Barnett MJ,Forrest DL,Lavoie JC,Nevill TJ,Nantel SH,Shepherd JD,Smith CA,Sutherland HJ,Toze CL,Crump M,Keating A

    更新日期:2005-04-01 00:00:00

  • Monoclonal B-cell lymphocytosis: a reappraisal of its clinical implications.

    abstract::Monoclonal B-cell lymphocytosis (MBL) is a recently defined medical condition that displays biological similarities to chronic lymphocytic leukemia (CLL), the most common subtype of adult leukemia in the Western world. MBL may be diagnosed in individuals with a normal lymphocyte count via a screening assay (screening ...

    journal_title:Leukemia & lymphoma

    pub_type: 杂志文章,评审

    doi:10.3109/10428194.2012.666542

    authors: Molica S,Mauro FR,Molica M,Del Giudice I,Foà R

    更新日期:2012-09-01 00:00:00